Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders?
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on X:
“Are Immune Checkpoint Inhibitors (ICIs) Safe for Patients with Neurologic Autoimmune Disorders (NAIDs)?
A multicenter study of 135 cancer patients with NAIDs sheds light:
- Myasthenia Gravis (MG): Highest risk — 67% had neurologic exacerbations, some severe or fatal.
- Multiple Sclerosis (MS): 18% experienced flares — generally milder.
- Guillain-Barré (GBS): No exacerbations observed, but 1 fatal immune-related event.
- Survival Outcomes: No difference in PFS or OS across NAID groups.
Takeaway: ICIs may be viable for many with NAIDs, but caution is crucial, especially in MG.”
Title: Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders
Authors: Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael Manos, Alexander M. Menzies, Frank Aboubakar-Nana, Jessica C. Hassel, David J. Pinato, Alexandra Johnson, Anna C. Olsson-Brown, Matteo S. Carlino, Andrea Malgeri, Alessio Cortellini, Aditi Singh, Kaushal Parikh, So Yeon Kim, Abdul Rafeh Naqash, Georgina V. Long, Pavan Challa, Toni K. Choueiri, Elad Sharon, Shailee Shah, Douglas B. Johnson
Read The Full Article at JAMA Network.
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023